AI-Powered Stethoscope - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI-powered stethoscope market is expected to grow from USD 132.70 million in 2025 to USD 139.63 million in 2026 and is forecasted to reach USD 189.66 million by 2031 at 6.32% CAGR over 2026-2031. This report is Segmented by Product Type (Wireless AI Stethoscope, Wired AI Stethoscope), Technology (Machine Learning, Deep Learning, and More), Application (Cardiology, Pulmonology, and More), End-User (Hospitals, Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global AI-Powered Stethoscope Market Trends and Insights

Rising Cardiovascular and Respiratory Disease Burden

The cardiovascular burden remains the clearest demand base for the AI-powered stethoscope market because routine auscultation is still the first screening step in many care settings. A PubMed-indexed study also projected a 90% increase in cardiovascular disease prevalence and a 73.4% rise in crude mortality between 2025 and 2050, driven by aging, inactivity, and metabolic risk exposure. In February 2026, research highlighted by the European Society of Cardiology showed that an AI-enabled digital stethoscope reached 92.3% sensitivity for moderate to severe valvular heart disease, versus 46.2% for a traditional stethoscope, across 357 patients in 3 primary care settings. That performance matters because it allows generalist clinicians to identify more patients who need specialist review before the disease progresses. This pattern supports the AI-powered stethoscope market not just as a device upgrade, but as a way to shorten the path between first contact, detection, and referral.

Expansion of Telemedicine and Remote Patient Monitoring

Telemedicine has become a durable care channel, which is pulling the AI-powered stethoscope market toward devices that can create shareable and clinically usable sound records outside hospitals. India’s government-backed eSanjeevani platform delivered more than 100 million consultations, which shows how large virtual care workflows have become in frontline public health delivery. In these workflows, the device is useful only when the recording can be transmitted, stored, and reviewed by a remote clinician without loss of context. That is why wireless platforms with app connectivity, structured recordings, and cleaner file transfer are gaining attention in primary care, homecare, and rural screening programs. The strongest near-term pull is coming from nurses, paramedics, and community health workers who need a practical screening tool at the edge of a teleconsultation workflow. As remote care becomes more routine, the AI-powered stethoscope market gains from its ability to turn an in-person listening task into digital clinical evidence that can travel between sites.

High Upfront Device and Algorithm Integration Cost

High ownership cost remains one of the clearest brakes on the AI-powered stethoscope market, especially in smaller clinics and rural systems with tight procurement budgets. Eko Health listed the CORE 500 at USD 379 and its Eko+ membership at USD 119.99 per year, while Lapsi Health priced the Keikku 2.0 at USD 375 when it launched in October 2025. That pricing gap is meaningful because hospitals may absorb subscription costs more easily than independent physicians, primary care chains, or public health programs can. The challenge is not limited to the device price, since recurring software fees, app support, training time, and integration work all shape the total cost of ownership. Buyers who are used to one-time device procurement often move more slowly when the product includes annual software charges without a clear reimbursement pathway. Until reimbursement and budget treatment become more predictable, adoption in the AI-powered stethoscope market will remain stronger in better-funded health systems than in cost-sensitive care environments.

Other drivers and restraints analyzed in the detailed report include:

• AI-Enabled Diagnostic Decision Support at Point of Care
• Need for Faster Triage in Primary Care and Emergency Settings
• Data Privacy and Cybersecurity Concerns in Connected Devices

Segment Analysis

Wireless devices accounted for 43.18% of revenue in 2025, which made them the leading format in the AI-powered stethoscope market. Their lead reflects clear clinician preference for Bluetooth-enabled devices that can pair with smartphones and connect to apps without tethered recording limits. These devices fit well into outpatient clinics, telemedicine workflows, and home health environments where captured sounds need to move quickly between providers. The value is not only convenience, because wireless sharing also makes second opinions and asynchronous review more practical. This is one reason the AI-powered stethoscope market has seen strong interest in platforms that combine mobility with cleaner recording quality.

Wired devices are expected to be the fastest-growing product sub-segment, with the AI-powered stethoscope market size for wired platforms projected to expand at a 7.54% CAGR through 2031. Institutional buyers continue to favor wired systems when they want more stable connections, lower per-device cost, and easier use in high-volume clinical settings. Teaching hospitals and academic centers also value wired configurations when multiple listeners need reliable playback for training purposes. Some buyers further see wired transmission as a simpler way to reduce exposure to wireless security concerns in controlled clinical spaces.

Machine learning held 39.26% of revenue in 2025, which placed it at the core of the AI-powered stethoscope market. The segment benefits from a longer development history in cardiac sound classification and from the large proprietary datasets built by early leaders. Deep learning methods add performance benefits in sound feature extraction, but they also require heavier compute resources that still limit embedded on-device use in many settings.

Natural language processing is anticipated to be the fastest-growing technology segment, with the AI-powered stethoscope market for NLP-driven solutions forecasted to rise at an 8.12% CAGR through 2031. Growth is tied to the way the device is changing from a listening tool into a documentation and decision support platform. Research presented through the Machine Learning for Health community showed that audio language models such as CaReAQA can generate grounded clinical responses from cardiac and respiratory audio, which signals a broader move toward explanation and workflow support instead of simple classification. This matters because clinicians often trust a result more when the system can organize and describe what it detected in usable language.

Complete Report Scope:

• By Product Type
  • Wireless AI Stethoscope
  • Wired AI Stethoscope
• By Technology
  • Machine Learning
  • Deep Learning
  • Natural Language Processing
  • Other Technologies
• By Application
  • Cardiology
  • Pulmonology
  • Pediatrics
  • Primary Care
  • Other Applications
• By End-User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.73% of revenue in 2025, which made it the largest regional block in the AI-powered stethoscope market. The region benefits from early FDA clearances, stronger enterprise purchasing capacity, and greater readiness to adopt software-supported bedside tools. The United States remains the core country market, with Eko Health reporting more than 650,000 SENSORA devices sold globally by 2025 and raising USD 41 million in Series D funding in June 2024 to scale AI-driven heart and lung disease detection. This leads matters because it gives North American vendors more opportunities to build datasets, refine workflows, and deepen provider familiarity in routine practice. Europe remains important for the AI-powered stethoscope market because strict evidence and privacy expectations can reward platforms that combine clinical validation with stronger compliance discipline.

Asia-Pacific is anticipated to be the fastest-growing region in the AI-powered stethoscope market, with a projected 8.95% CAGR through 2031. Growth is being shaped by large unmet screening needs, expanding digital health delivery, and a stronger policy focus on extending specialist reach through technology-enabled frontline care. India stands out because NITI Aayog highlighted both the specialist shortfall and the role of AI-based auscultation in helping frontline workers screen patients earlier. The region’s faster growth suggests that the AI-powered stethoscope market will expand not only through premium hospital purchases but also through devices adapted for wider first-line use.

The Middle East, Africa, and South America remain earlier-stage parts of the AI-powered stethoscope market, where infrastructure gaps and price sensitivity still slow broad adoption. Even so, long-term demand is meaningful because these regions continue to face specialist access gaps and uneven connectivity across many care settings. Platforms designed for affordability, portability, and offline or low-bandwidth use are better positioned here than premium subscription-led models. Sonavi Labs’ emphasis on home auscultation and secure sharing shows why simpler deployment models may matter more than feature depth in these geographies.

List of Companies Covered in this Report:

• A&D Company, Limited
• ADInstruments Pty Ltd
• Aevice Health
• American Diagnostic
• Cardionics, Inc.
• CliniCloud
• Contec Medical Systems
• Eko Health
• eKuore Medical
• HD Medical Group
• Lapsi Health
• M3DICINE Pty Ltd.
• Meditech Equipment
• SensiCardiac
• Solventum
• Sonavi Labs
• StethoMe
• Thinklabs Medical LLC
• Welch Allyn

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support